Approval Year
| Substance Class |
Protein
Created
by
admin
on
Edited
Sun Dec 18 09:05:50 UTC 2022
by
admin
on
Sun Dec 18 09:05:50 UTC 2022
|
| Protein Type | RECEPTOR |
| Protein Sub Type | HYDROXYTRYPTAMINE RECEPTOR |
| Sequence Origin | HUMAN |
| Sequence Type | COMPLETE |
| Record UNII |
6E2Z4UWILI
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
P41595
Created by
admin on Sun Dec 18 09:05:53 UTC 2022 , Edited by admin on Sun Dec 18 09:05:53 UTC 2022
|
PRIMARY | |||
|
6E2Z4UWILI
Created by
admin on Sun Dec 18 09:05:53 UTC 2022 , Edited by admin on Sun Dec 18 09:05:53 UTC 2022
|
PRIMARY |
| From | To |
|---|---|
| 1_128 | 1_207 |
| 1_350 | 1_353 |
| Glycosylation Type | HUMAN |
| Glycosylation Link Type | Site |
|---|---|
| N | 1_30 |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARTIAL AGONIST->TARGET |
|
||
|
|
INHIBITOR -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
INHIBITOR -> TARGET |
Ki
|
||
|
PARTIAL AGONIST->TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
AGONIST->OFF-TARGET |
5-HT2B receptors, which were subsequently identified as the target for cardiac valvulopathy and pulmonary hypertension. Release of serotonin leads to 5-HT2B signaling.
|
||
|
WEAK AGONIST->OFF TARGET |
Ki
|
||
|
RADIOLIGAND->TARGET |
Ki
|
||
|
AGONIST -> TARGET |
Eletriptan binds with high affinity to 5-HT1B, 5-HT1D and 5-HT1F receptors, has modest affinity for 5-HT1A, 5-HT1E, 5-HT2B and 5-HT7 receptors
|
||
|
INHIBITOR -> TARGET |
Acts as a mixed antagonist for the 5-HT2B and 5-HT2C serotonin receptors, with good selectivity over other serotonin receptor subtypes and slight preference for 5-HT2C over 5-HT2B.
ANTAGONIST
|
||
|
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
ANTAGONIST
|
||
|
PARTIAL AGONIST->TARGET | |||
|
|
INHIBITOR -> TARGET |
Ki
|
||
|
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
ANTAGONIST
|
||
|
|
INVERSE AGONIST->TARGET |
IC50
|
||
|
|
INHIBITOR -> TARGET |
Ki
|
||
|
|
INHIBITOR -> TARGET |
|
||
|
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET | |||
|
INHIBITOR -> TARGET |
|
||
|
AGONIST -> TARGET | |||
|
WEAK AGONIST->OFF TARGET |
Emax,40%
|
||
|
AGONIST -> TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
|
AGONIST->OFF-TARGET |
5-HT2B receptors, which were subsequently identified as the target for cardiac valvulopathy and pulmonary hypertension. Release of serotonin leads to 5-HT2B signaling.
|
||
|
|
INHIBITOR -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
INHIBITOR -> TARGET |
Ki
|
||
|
INHIBITOR -> TARGET |
ANTAGONIST
|
||
|
|
AGONIST -> TARGET |
We propose that preferential stimulation of valvular 5-HT2B receptors by norfenfluramine, ergot drugs, or 5-HT released from carcinoid tumors (with
or without accompanying 5-HT2A receptor activation) may contribute to valvular fibroplasia in humans.
Ki
|
||
|
AGONIST -> TARGET |
Ki
|
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Molecular Formula | CHEMICAL |
|
||||
| MOL_WEIGHT | CHEMICAL |
|